SCHEMBL271883

SCHEMBL271883

CCOC(=O)CC(C=O)C(=O)OCC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.44
GAA P10253 1/20 0.44
SI P14410 1/20 0.44
MGAM2 Q2M2H8 1/20 0.44
ALDH1A1 P00352 7/20 0.42
ALOX15 P16050 3/20 0.42
CYP3A4 P08684 2/20 0.42
TSHR P16473 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
TRPA1 O75762 1/20 0.41
HSD17B10 Q99714 2/20 0.41
CHRM1 P11229 1/20 0.41
ADORA1 P30542 1/20 0.41
MET P08581 1/20 0.38
CYP2D6 P10635 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CYP1A2 P05177 1/20 0.36
LMNA P02545 1/20 0.36
KMT2A Q03164 2/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15598396 0.89 MGAM (0.39) MGAMGAASIMGAM2ALDH1A1
SCHEMBL17376202 0.88 GAA (0.46) MGAMGAASIMGAM2ALDH1A1
SCHEMBL27654778 0.86 MGAM (0.43) MGAMGAASIMGAM2ALDH1A1
SCHEMBL9686224 0.83 HCAR2 (0.38) MGAMGAASIMGAM2ALDH1A1
SCHEMBL4685380 0.83 ALDH1A1 (0.41) MGAMGAASIMGAM2ALDH1A1
SCHEMBL15581613 0.82 MGAM (0.43) MGAMGAASIMGAM2ALDH1A1
SCHEMBL1495985 0.80 ALDH1A1 (0.42) MGAMGAASIMGAM2ALDH1A1
SCHEMBL7840946 0.80 MGAM (0.41) MGAMGAASIMGAM2ALDH1A1
SCHEMBL6160354 0.80 L3MBTL1 (0.50) MGAMGAASIMGAM2ALDH1A1
SCHEMBL3841717 0.79 L3MBTL1 (0.49) MGAMGAASIMGAM2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113620977-A Synthesis method of thiazolidine pyrimidone acetic acid 江苏弘和药物研发有限公司 2021-11-09 CN claimed
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
CN-113620977-B Synthesis method of thiazolopyrimidinone acetic acid 江苏弘和药物研发有限公司 2024-02-02 CN disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed
US-20230065740-A1 CYCLIN-DEPENDENT KINASE INHIBITORS SPV THERAPEUTICS INC. 2023-03-02 US disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
CN-113620977-A Synthesis method of thiazolidine pyrimidone acetic acid 江苏弘和药物研发有限公司 2021-11-09 CN disclosed
EP-2675793-B1 FAK INHIBITORS CANCER THERAPEUTICS CRC PTY LTD (AU) 2018-08-08 EP disclosed
US-20160367557-A1 HETEROCYCLIC PYRIMIDINE CARBONIC ACID DERIVATIVES WHICH ARE USEFUL IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE SAVIRA PHARMACEUTICALS GMBH 2016-12-22 US disclosed
US-5155103-A Methods of using new thieno-triazole-1,4-diazepino-2-carboxylic acid amides BOEHRINGER INGELHEIM GMBH (DE) 1992-10-13 US disclosed
US-5116971-A Platelt-activating-factor antagonist BOEHRINGER INGELHEIM KG (DE) 1992-05-26 US disclosed
EP-0188094-B1 QUINAZOLINE DERIVATIVES AND ANTIHYPERTENSIVE PREPARATIONS CONTAINING SAME AS EFFECTIVE COMPONENTS MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1992-03-18 EP disclosed
US-5082839-A Platelet activating factor antagonist BOEHRINGER INGELHEIM GMBH (DE) 1992-01-21 US disclosed
US-4968794-A ANTAGONISTS OF PLATELET ACTIVATING FACTOR BOEHRINGER INGELHEIM KG (DE) 1990-11-06 US disclosed
US-4734418-A Quinazoline compounds and antihypertensives MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1988-03-29 US disclosed
EP-0188094-A2 Quinazoline derivatives and antihypertensive preparations containing same as effective components MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1986-07-23 EP disclosed
US-4190657-A ANTI-ANOXIA AND PSYCHOTROPIC ACTIVITY SYNTHELABO (FR) 1980-02-26 US disclosed
US-4089858-A Heterocyclic-amino-acrylic acid derivatives CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) 1978-05-16 US disclosed
US-4024159-A Process for the production of liquid acetals E. I. DU PONT DE NEMOURS AND COMPANY (US) 1977-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230065740-A1 CYCLIN-DEPENDENT KINASE INHIBITORS CDK2, CDK1, CCNK MGAM 3918/4885GAA 3009/4885SI 4264/4885
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT MGAM 1969/4885GAA 84/4885SI 945/4885
US-20160367557-A1 HETEROCYCLIC PYRIMIDINE CARBONIC ACID DERIVATIVES WHICH ARE USEFUL IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE ALAD, XDH, UACA MGAM 2737/4885GAA 125/4885SI 1099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.